Compare RWT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | PHVS |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | Switzerland |
| Employees | 351 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.5M | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | RWT | PHVS |
|---|---|---|
| Price | $5.71 | $28.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $6.91 | ★ $40.60 |
| AVG Volume (30 Days) | ★ 1.4M | 186.7K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 12.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.59 | N/A |
| Revenue Next Year | $22.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.68 | $11.51 |
| 52 Week High | $6.97 | $29.85 |
| Indicator | RWT | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 50.00 | 58.97 |
| Support Level | $5.39 | $24.55 |
| Resistance Level | $5.90 | $29.80 |
| Average True Range (ATR) | 0.17 | 1.22 |
| MACD | 0.03 | 0.27 |
| Stochastic Oscillator | 66.88 | 74.69 |
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.